On This Day in Health: July 31, 1990
On July 31, 1990, the National Institutes of Health Recombinant DNA Advisory Committee approved the first protocols to transfer human genes for therapeutic purposes. One proposal targeted adenosine deaminase deficiency, a rare inherited cause of severe combined immunodeficiency, or ADA-SCID. The disorder leaves children with dangerously weak immune defenses because mutations prevent production of a working ADA enzyme. The public committee review did not itself treat a patient, and other regulatory steps still applied. It nevertheless marked the moment when years of laboratory research, safety debate, and ethical scrutiny produced authorization to attempt gene therapy as medicine.
The ADA-SCID protocol was developed by NIH researchers W. French Anderson, R. Michael Blaese, and colleagues. Their plan used an ex vivo method: remove some of a patient's T cells, grow them outside the body, introduce a working ADA gene with a disabled retroviral vector, and return the modified cells by infusion. Because the altered cells were not expected to last forever, treatment would be repeated. Participants would continue receiving PEG-ADA enzyme replacement, which provided a safety net but made it harder to isolate the gene therapy's effects. The approach targeted somatic immune cells, so genetic changes were not intended to pass to future generations.
On September 14, four-year-old Ashanti DeSilva received the first infusion in the ADA-SCID trial. A second girl entered treatment in January 1991. Follow-up showed that genetically modified cells persisted and produced ADA, while immune measurements improved. The children still relied on other treatment, and the trial did not establish a complete cure. Its greatest achievement was demonstrating that researchers could remove human cells, add a functional gene, return the cells, and monitor them over time without the feared immediate catastrophe. The careful result supplied evidence for a field that had previously existed mainly in animal experiments, molecular theory, and public controversy.
Gene therapy later experienced both major advances and grave setbacks, including deaths, immune reactions, and cancers linked to some early vectors. Those events strengthened oversight and drove development of safer delivery systems, better manufacturing, and longer follow-up. Modern gene therapies can replace genes, silence harmful activity, or genetically engineer immune cells, and several have received regulatory approval for inherited disorders and cancers. Access, cost, durability, and long-term risk remain difficult questions. The July 31 vote therefore represents neither instant success nor an uncomplicated beginning. It was a governance milestone that permitted a cautious human experiment and established a precedent for evaluating powerful genetic interventions in public.
NIH's Recombinant DNA Advisory Committee publicly reviewed scientific, safety, and ethical questions surrounding experiments that would introduce genes into human cells.
On July 31, 1990, it approved therapeutic protocols for ADA-SCID and cancer, moving human gene transfer from preliminary marking studies toward attempted treatment.
The ADA-SCID plan modified a patient's own T cells outside the body with a retroviral vector carrying a functional ADA gene, then returned the cells by infusion.
Patients continued enzyme replacement, the modified cells were not a permanent cure, and the protocol required repeated treatments and intensive monitoring.
The first infusion on September 14, 1990 showed that gene-modified cells could persist and express ADA, establishing a practical proof of concept for therapeutic gene transfer.
Later successes and serious setbacks reshaped vectors and oversight, while modern gene therapies expanded into inherited disease and cancer with continuing concerns about safety and access.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.